iRhythm is pushing its heart-monitoring patch beyond specialist clinics by winning over primary care doctors and expanding overseas, helped by partnerships and smarter software. But tougher regulators, rising competition, and ongoing cash burn could slow momentum just as the business needs to prove it can scale profitably.Read more
Catalysts About iRhythm Holdings iRhythm Holdings provides ambulatory cardiac monitoring services using wearable biosensors, AI tools and integrated clinical workflows. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About iRhythm Holdings iRhythm Holdings provides ambulatory cardiac monitoring services built around its Zio biosensor platform and related analytics. What are the underlying business or industry changes driving this perspective?Read more
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
